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Rett syndrome (RTT) is a rare neurodevelopmental disorder, characterized by severe
behavioral and physiological symptoms. Mutations in the methyl CpG binding protein 2
gene (MECP2) cause more than 95% of classic cases, and currently there is no cure
for this devastating disorder. Recently we have demonstrated that specific behavioral
and brain molecular alterations can be rescued in MeCP2-308 male mice, a RTT mouse
model, by pharmacological stimulation of the brain serotonin receptor 7 (5-HT7R). This
member of the serotonin receptor family—crucially involved in the regulation of brain
structural plasticity and cognitive processes—can be stimulated by systemic repeated
treatment with LP-211, a brain-penetrant selective 5-HT7R agonist. The present study
extends previous findings by demonstrating that the LP-211 treatment (0.25 mg/kg,
once per day for 7 days) rescues RTT-related phenotypic alterations, motor coordination
(Dowel test), spatial reference memory (Barnes maze test) and synaptic plasticity
(hippocampal long-term-potentiation) in MeCP2-308 heterozygous female mice, the
genetic and hormonal milieu that resembles that of RTT patients. LP-211 also restores
the activation of the ribosomal protein (rp) S6, the downstream target of mTOR and
S6 kinase, in the hippocampus of RTT female mice. Notably, the beneficial effects on
neurobehavioral and molecular parameters of a seven-day long treatment with LP-211
were evident up to 2 months after the last injection, thus suggesting long-lasting effects
on RTT-related impairments. Taken together with our previous study, these results
provide compelling preclinical evidence of the potential therapeutic value for RTT of a
pharmacological approach targeting the brain 5-HT7R.
Keywords: serotonin, neurodevelopmental disorders, intellectual disability, transgenic mice, synaptic plasticity,
Rho GTPases, cognition
Introduction
The serotonin receptor 7 (5-HT7R), coded by Htr7 gene, is among the most recently discovered
serotonin receptors (Barnes and Sharp, 1999). This seven-transmembrane and G protein-coupled
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receptor is characterized by a widespread expression in the
central nervous system and in the periphery (Romano et al.,
2014). The highest 5-HT7 receptor density in the brain is
found in the thalamus and hypothalamus, as well as in the
hippocampus (Guseva et al., 2014). Thanks to the availability
of pharmacological and genetic tools targeting the 5-HT7R in
preclinical models (Leopoldo et al., 2011; Matthys et al., 2011),
a link with neuro-physiological phenomena like regulation of
the circadian rhythm, sleep, mood and thermoregulation has
been clearly established (Matthys et al., 2011; Adriani et al.,
2012; Monti and Jantos, 2014). The relevance of the 5-HT7R
in various psychiatric and neurological disorders, such as
anxiety, schizophrenia, pain and epilepsy has been also addressed
(Hedlund, 2009; Di Pilato et al., 2014). An increasing number
of studies demonstrates a role for the 5-HT7R on cognitive
processes (particularly on hippocampal-dependent learning and
memory) and in the regulation of structural plasticity in
adolescent and mature brain circuits (Gasbarri and Pompili,
2014; Meneses, 2014; Volpicelli et al., 2014; Canese et al.,
2015). Consistent with these observations, the 5-HT7R activation
stimulates signaling cascades known to play a prominent role
in synaptic plasticity and cognition, with the more prominent
downstream effectors being represented by the extracellular-
signal regulated kinases (ERKs), the cyclic AMP protein kinase
(PKA) and the Cyclin-dependent kinase 5 (Cdk5; Guseva et al.,
2014; Volpicelli et al., 2014).
In cultured hippocampal neurons, receptor-mediated
activation of the Gα12 signaling pathway also results in the
selective activation of small Rho GTPases (Kvachnina et al.,
2005; Kobe et al., 2012), a family of proteins crucially involved
in neuronal plasticity and cognition and key regulators of
actin cytoskeleton dynamics (De Filippis et al., 2014b). The
5-HT7R-mediated stimulation of this signaling pathway
leads to pronounced changes in neuronal morphology and
plasticity (Kobe et al., 2012), thus providing further support
to a crucial involvement of 5-HT7R in the regulation of
neurobiological mechanisms underlying cognitive functions
(Volpicelli et al., 2014). Recently, we have extended these
findings by providing the first in vivo evidence that a
pharmacological stimulation of the 5-HT7R (i.e., by systemic
administration of LP-211, a novel selective and brain penetrant
5-HT7R agonist: see (Hedlund et al., 2010; Romano et al.,
2014), activates Rho GTPases in mouse brain (De Filippis
et al., 2014a). Given the involvement of brain Rho GTPases
in a number of neurological disorders and the paucity of
drugs targeting this family of proteins in vivo (De Filippis
et al., 2014b), these data pointed to LP-211 as an innovative
pharmacological tool to be exploited in preclinical research.
In this line, activation of 5-HT7Rs has been reported to
reverse electrophysiological abnormalities in hippocampal slices
collected from a mouse model of Fragile X syndrome (Costa
et al., 2012).
Based on these findings, we have recently investigated the
potential therapeutic value of a pharmacological stimulation
of the central 5-HT7R for Rett syndrome (RTT), a rare
and severe neurodevelopmental disorder (Percy and Lane,
2005) and one of the leading causes of mental disability
in girls (Rett, 1966; Hagberg, 2002). RTT patients present
stereotypical hand movements, limited language, severe
autistic−like features and intellectual disability, as well
as potentially life−threatening seizures and respiratory
dysfunction. Mutations in the methyl-CpG-binding protein
2 (MeCP2) gene, located on Xq28, have been identified as the
main genetic cause of RTT (Amir et al., 1999) and account for
more than 95% of classic RTT (Chahrour and Zoghbi, 2007).
At present there is no cure for RTT and available treatments are
symptomatic.
Consistent with previous evidence pointing to Rho GTPases
as therapeutic targets for RTT (De Filippis et al., 2012) and with
previous studies suggesting that serotonergic neurotransmission
is deeply affected both in RTT patients and animal models
(Isoda et al., 2010; Santos et al., 2010; Moroto et al., 2013),
we demonstrated that a seven-day-long treatment with LP-211
reverses anxiety-related profiles in a Light/Dark test, motor
abilities in a Dowel test, the exploratory behavior in the Marble
Burying test, as well as short-term working memory in the Y
maze task in MeCP2-308 hemizygous (hz) male mice (Ricceri
et al., 2013). Moreover, this treatment was found to restore the
activation of Rho GTPases effector molecules, PAK, cofilin and
the ribosomal protein (rp) S6, a downstream target of mTOR and
S6 kinase (Ricciardi et al., 2011), in RTTmouse hippocampus (De
Filippis et al., 2014a).
In the present study, we aimed at assessing whether the
beneficial effects of the LP-211 treatment in RTT mice extend
beyond the behavioral domains we had previously investigated
(De Filippis et al., 2014a). To increase the translational value
of the study, we focused on MeCP2-308 heterozygous (Het)
female mice, given that their genetic and hormonal milieu
more closely resembles that of RTT patients (Katz et al.,
2012). Increasing studies in fact demonstrate that heterozygosity
does not preclude the use of female mice in RTT preclinical
studies (Woods et al., 2012; Garg et al., 2013). Therefore, in
symptomatic MeCP2-308 Het female mice, we have evaluated
whether treatment with LP-211 affects spatial reference memory
deficits in the Barnes Maze test and impairments of hippocampal
long-term potentiation (LTP), a form of synaptic plasticity
thought to underline long-term memory formation. Given the
demonstrated role played by 5-HT7R in the regulation of
cognitive performance and synaptic plasticity (Gasbarri and
Pompili, 2014; Meneses, 2014; Volpicelli et al., 2014), we
argued that 5-HT7R stimulation by LP-211 in RTT mouse
brain might restore these additional RTT-related deficits.
Moreover, in order to confirm data obtained in LP-211-treated
MeCP2-308 male mice (De Filippis et al., 2014a) and assess
whether this treatment is equally effective under conditions of
heterozygosis, the effects of the treatment on motor coordination
deficits in RTT female mice were also addressed with the
Dowel test.
Another major aim of the present study was to discover
whether a seven-day-long treatment with LP-211 may produce
long-lasting changes in the neurobehavioral phenotype or at
the brain molecular level in RTT mice. This hypothesis stems
from previous studies demonstrating that transient modulation
of Rho GTPases in RTT mouse brain produces long-lasting
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beneficial effects (De Filippis et al., 2012) and that 5-HT7
stimulation during periods of increased plasticity, such as
adolescent age, may result in neuro-plastic changes leading
to a persistent modification on forebrain circuits (Adriani
et al., 2006; Altabella et al., 2014; Canese et al., 2015).
To evaluate this hypothesis, we applied the seven-day-long
treatment schedule known to induce Rho GTPases activation
in mouse brain (De Filippis et al., 2014a) and tested the effects
on general health parameters as well as behavioral, molecular
and synaptic plasticity endpoints up to 2 months after the last
injection).
Materials and Methods
Subjects
The experimental subjects were 1-year old MeCP2-308
heterozygous female mice [B6.129S-MeCP2tm1Heto/J, stock
number: 005439; backcrossed to C57BL/6J mice for at least 12
generations from the Jackson Laboratories (USA)] and wild-type
(wt) littermates. The MeCP2-308 model bears a truncating
mutation, leading to the expression of a protein truncated at
amino acid 308 (Shahbazian et al., 2002). In agreement with
clinical data from RTT patients carrying C-terminal deletions of
the MeCP2 gene (Díaz de León-Guerrero et al., 2011), this model
presents a delayed onset of symptoms and a prolonged life-span
in comparison with knockout mice (Ricceri et al., 2008).
Mice were housed in groups of 2–3 in polycarbonate
transparent cages (33 × 13 × 14 cm) with sawdust bedding
and kept on a 12-h light-dark schedule (lights off at 8:00).
Temperature was maintained at 21 ± 1◦C and relative humidity
at 60 ± 10%. Animals were provided ad libitum with tap water
and a complete pellet diet (Altromin, Germany). All procedures
were carried out in accordance with the European Communities
Council Directive (86/609/EEC) as well as Italian law, and
formally approved by Italian Ministry of Health.
Drug and Treatment
LP-211 was prepared following the same synthetic procedure
described in Leopoldo et al. (2008). The compound was dissolved
in a vehicle solution of 1% dimethyl sulfoxide (DMSO) in
saline (0.9% NaCl). MeCP2-mutated mice and wt littermate
controls were randomly assigned to be daily intra-peritoneally
(ip) injected (between 9.00 and 11.00 am) for 7 consecutive days
with either LP-211 (0.25 mg/kg) or vehicle (1% of DMSO in
saline). The number of mice for each condition was as follows:
wt, Veh = 9; wt, LP-211 = 11; Het, Veh = 12; Het, LP-211 = 10.
To test whether LP-211 can counteract RTT related
abnormalities when they are fully manifested, MeCP2-308
heterozygous female mice were treated at about 1 year of
age, when abnormalities have been reported to start appearing
(Shahbazian et al., 2002).
Behavioral Testing
Mice were experimentally naïve at the start of the test battery.
All behavioral testing took place during the dark phase of the
L/D cycle, between 9.00 am and 6.00 pm, and was carried out
by experimenters blind to mouse genotypes and treatments.
The estrous cycle was not controlled in this study (Prendergast
et al., 2014). A minimum of 24 h was left between each test,
as follows: the Dowel test was performed 2 h after the 7th ip
injection; the open field test was carried out 24 h after the
last ip injection (on the 8th day of the schedule); the general
health scoring was carried out after the open field test on the
8th day of the schedule and 23 days after the last ip injection
(on the 30th day of the schedule); the training on the Barnes
Maze test started on the 14th day of the schedule and the
probe tests were conducted on the 21st and 28th days of the
schedule (see Figure 1 for experimental design and treatment
schedule).
General Health Scoring
The general health of the experimental mice was qualitatively
evaluated by a trained observer as previously described (Guy
et al., 2007; De Filippis et al., 2014a), with little modification.
Briefly, mice received a score (ranging from 0: normal
appearance, to 2: highly compromised) for each of the following
symptoms: gait, mobility, breathing, kyphosis, fur, hindlimb
clasping, tremors, general condition. The individual scores for
FIGURE 1 | Experimental Design.
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each of these categories were subsequently averaged to obtain a
semi-quantitative measure of individual symptom status, called
throughout the text ‘‘the general health score’’.
Body weight and body (rectal) temperature were recorded
after each general health scoring.
Dowel Test
To evaluate the effects of the LP-211 treatment on motor
coordination capacities, the Dowel test was performed as
previously described (De Filippis et al., 2014a). The hardwood
round dowel used was 9.0 mm in diameter and 35 cm long.
The dowel was mounted horizontally 50 cm above a 5 cm depth
bedding of sawdust. At the beginning of the each testing session,
each mouse was placed in the middle of the dowel so that the
length of its body was parallel to it. Latency to fall from the dowel
into a cage of bedding was recorded (30-s criterion). Each mouse
repeated the test three times, with an intertrial interval of at least
15 min. If mice were able to walk across the dowel and off of the
dowel, they received the maximum score of 30 s.
Open Field Test
The open field apparatus was a gray plastic box (40 × 40
cm) surrounded by high walls (35 cm). Each mouse was
individually placed in the open field and allowed to freely
explore the environment for a 60 min session (De Filippis
et al., 2013). The floor of the apparatus was cleaned with 20%
ethanol after each animal was tested and the test was carried
out under dim lights. Three intervals of 5 min (0–5; 30–35;
55–60) were subsequently scored by a trained observer blind
to the genotype and treatment of mice, using a computer and
a specific software (THE OBSERVER v2.0 for DOS, Noldus
Information Technology, Wageningen, Netherlands). The floor
of the apparatus was subdivided into 16 sections (10× 10 cm) by
lines placed on the video screen at the time of videotape analysis.
The frequency and durations of the following items were scored:
Crossing (number of line crossings with both forepaws), Rearing
(body in vertical position),Wall rearing (body in vertical position
with forepaws placed on the walls of the cage), Grooming (mouth
or paws on body) and Inactivity (complete absence ofmovements
including small movements of head, ears or vibrissae).
Barnes Maze Test
To assess whether the treatment with LP-211 has beneficial
effects on spatial reference memory deficits in RTT mice, the
Barnes Maze test was carried out as previously described (Barnes,
1979).
In this test, mice were trained to locate a black rectangular
escape box (7 × 37 × 9 cm) hidden underneath one of 12
holes (4 cm in diameter) evenly spaced around the perimeter
of an elevated (36 cm above the floor) gray platform (95 cm
in diameter), illuminated by overhead fluorescent white room
lighting (85 lux). The hole above the escape box was designated as
the target, analogous to the hidden platform in the Morris water
maze task. The location of the target was consistent for a given
mouse but randomized acrossmice. To prevent orientation to the
target before a trial began, mice were initially placed in the center
of the platform under a black cylinder (12 cm in diameter). The
cylinder was removed after 10 s and the trial begun. The maze
was cleaned with a 20% ethanol solution between each trial.
Behavioral testing consisted of an adaptation period, an
acquisition phase and 2 probe trials. During the adaptation phase
(14th day of the schedule), mice were allowed to explore for two
consecutive daily trials the platform. During each trial, if 1 min
had elapsed without the mice entering the target hole, they were
placed to the side of the target hole and gently helped to enter the
escape box. Once inside the escape box, the mouse was left there
for 2 min. No parameters were recorded during this phase.
During the acquisition phase (from the 15th to the 20th day
of the schedule), mice were given two trials per day during
which latency to enter the target hole and total path length were
recorded. When the trial ended (i.e., when the mouse entered
the escape box or after 3 min had elapsed), the mouse was left
inside the escape box for 1 min. An intertrial interval of at least
10 min was used. During the acquisition phase, latency, errors
and path length to enter the target hole were measured. For
statistical analyses parameters were averaged in blocks of trials
per day (mean± S.E.M).
The first probe trial was conducted 24 h after the last training
trial to assess short-term reference memory retention (21th day
of the schedule). To assess long-term retention a second probe
trial was applied 7 days after the first probe (28th day of the
schedule). No training trials were conducted between the two
probe tests. During the probe tests, the target hole was closed to
confirm that mice used only extra-maze cues to reach the escape
box. A 90-s long session was used, during which primary latency
(to first nose poke in the virtual target hole) and primary errors
(i.e., nose pokes before arriving to the target) were measured.
Neurobiological Analyses
Starting on the 40th day of the schedule, mice underwent
electrophysiology experiments (N = 4 mice per experimental
group). The brains of the remaining subjects were dissected and
rapidly frozen for biochemical analyses at sacrifice, 2 months
after the last ip injection.
Hippocampal Slice Electrophysiology
To evaluate the induction of LTP in wt and MeCP2-308 female
mice, hippocampal slices were prepared as previously described
(Domenici et al., 2006). Field excitatory post-synaptic potentials
(fEPSPs) were recorded in stratum radiatum of CA1 area after
stimulation of the Schaffer collaterals. Traces were acquired,
amplified and analyzed with DAM-80 AC differential amplifier
(WPI Instruments) and with the WinLTP software (Anderson
and Collingridge, 2007). Stimuli (100 µs duration) were set to an
intensity that evokes a fEPSPwith a slope of 60% of themaximum
fEPSP slope and delivered every 20 s (three consecutive responses
were averaged). LTP was induced by a theta-burst stimulation
(TBS) consisting in 2 trains of 5 sets of bursts (four stimuli,
100 Hz) with an interburst interval of 200 ms and a 20 s
interval between each train. Synaptic transmission was recorded
for 60min and 10min of stable baseline recordings preceded LTP
induction. Changes in fEPSP slope were expressed as percentage
changes with respect to the average slope of the fEPSP measured
during the 10 min that preceded the TBS.
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Western Blot Analyses
Proteins were analyzed by western blotting as previously
described (De Filippis et al., 2014a). Briefly, hippocampal tissues
were isolated and homogenized in lysis buffer immediately after
sacrifice, proteins were separated by SDS-PAGE and blotted
to nitrocellulose membrane. The following primary antibodies
were used: rabbit polyconal anti-rpS6 (1:1000, cod. 2217, Cell
Signaling), rabbit polyclonal anti-phospho-rpS6 (1:200, cod. 2211
(Ser 235/236) and cod. 2215 (Ser 240/244), Cell Signaling), mouse
monoclonal anti β-actin (1:1000, cod. sc-81178, Santa Cruz).
Optical densities (O.D.) of the protein signals from at least
three different experiments were calculated for each sample and
normalized with the corresponding β-actin signal; the O.D. ratios
were then compared and expressed as the average fold increase,
with 1 (wt control) as baseline.
Statistical Analysis
Data were analyzed with either parametric or non-parametric
analysis of variance, depending on distribution of the response
variable considered. The Shapiro-Wilk test was applied to verify
the normality of data distribution. ANOVA models included
genotype (wt vs. Het) and treatment (vehicle vs. LP-211) as
between-subject factors, and repeated measurements as within-
subject factor. Post hoc comparisons were run using Tukey’s
test, which can be performed also in the absence of significant
ANOVA results (Wilcox, 1987). The Levene test was applied to
confirm that variance did not differ between groups. To unravel
the presence of outliers, the Grubbs’ test was applied.
Results
General Health Scoring
Kruskall Wallis analyses confirmed that significant differences
among the experimental groups are present on both time points
under investigation (first time interval: H = 8.89; p = 0.031;
second time interval: H = 9.31; p = 0.025; Figure 2). Post hoc
comparisons, carried out with theMannWhitney U test, revealed
that—at 24 h after the last ip injection—slight but reliable
phenotypic alterations can be detected in MeCP2-308 female
mice compared to wt controls (wt, Veh vs. Het, Veh: U = 23.50;
p = 0.030; Figure 2). In particular, the phenotypic parameters
which appeared most compromised in MeCP2-308 female mice
were the gait, the kyphosis and breathing. Contrary to MeCP2-
null mice (Guy et al., 2007), no hindlimb clasping or abnormal
mobility were observed in RTTmice vs. wt controls. At this point
of the treatment schedule (Figure 1), no recovery in the general
health status was observed for RTT mice treated with LP-211
compared to vehicle, with both being significantly worse than
wt controls (Figure 2). Notably, however, recovery was observed
3 weeks later: MeCP2-308 female mice that had received the
vehicle treatment were slightly worsened (wt, Veh vs. Het, Veh:
U = 18.00; p = 0.011), whereas RTT mice that were treated with
LP-211 exhibited an improved general health status (Het, Veh vs.
Het, LP-211: U = 29.00; p = 0.041; Figure 2). A delayed effect of
the 7-day long LP-211 treatment on general health status of RTT
mice was thus demonstrated.
FIGURE 2 | Treatment with LP-211 exerts delayed beneficial effects on
general health parameters in MeCP2-308 female mice. MeCP2-308
female mice (Het) showed slight but reliable phenotypic alterations compared
to wt mice in control conditions (Veh). The seven-day long LP-211 treatment
improved the general health status selectively in Het mice (Het, LP-211) after 3
weeks from the last injection. Mice for each condition were as follows: wt,
Veh = 9; wt, LP-211 = 11; Het, Veh = 12; Het, LP-211 = 10. Data are mean ±
SEM. e : wt, Veh vs. Het, Veh, p < 0.05 and * : Het, Veh vs. Het, LP-211,
p < 0.05.
No significant genotype nor treatment effects were found as
for body weight and body temperature (data not shown).
Dowel Test
Performance in the Dowel test on the 7th day of treatment
was investigated to confirm data obtained in LP-211-treated
MeCP2-308 hz male mice (De Filippis et al., 2014a). The
repeated measures (RM)- ANOVA yielded a significant main
effect of genotype (F(1,38) = 4.12; p = 0.049), with RTT mice
falling from the dowel significantly earlier than wt controls
(Figure 3), and a genotype by treatment interaction just missing
significance (F(1,38) = 3.77; p = 0.060). Post hoc comparisons
by Tukey’s test confirmed that the performance of MeCP2-308
heterozygous female mice was worse compared to that of wt
controls (p< 0.05). A just missing effect of the LP-211 treatment
on the motor coordination ability of RTT mice was also found,
with the treatment improving their performance (Figure 3). The
LP-211 treatment did not affect the performance of wt mice.
Open Field Test
In order to clarify LP-211 treatment effects on general locomotor
activity, MeCP2-308 mice and wt littermates were tested in the
open field test. The RM- ANOVA did not highlight any difference
between groups as for the mean number of crossings (wt Veh:
74.78 ± 5.69; wt LP-211: 69.67 ± 4.80; Het Veh: 79.53 ± 5.04;
Het LP-211: 75.47 ± 4.63) and the time mice spent in the central
area of the arena (wt Veh: 29.26 ± 7.18s; wt LP-211: 26.75
± 5.81; Het Veh: 27.06 ± 3.92; Het LP-211: 22.75 ± 4.20).
Mice also spent a similar amount of time being immobile or
performing self-directed grooming (data not shown). Mutant
mice however performed a significantly lower number of rearings
(wt (veh + LP-211 pooled): 34.88 ± 2.08; Het (veh + LP-211 pooled): 25.59
± 1.36; main effect of genotype: F (1,38) = 7.63; p = 0.009), thus
confirming previous reports (De Filippis et al., 2012). As a whole,
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FIGURE 3 | Treatment with LP-211 improves motor coordination
capacities of MeCP2-308 female mice in the Dowel test. (A) In the
Dowel test, MeCP2-308 female mice (Het, Veh) displayed significantly shorter
latencies to fall compared to wt controls (wt, Veh), confirming impaired motor
coordination capacities. LP-211 improved the performance of Het mice in this
test. Three trials per mouse were performed, with an intertrial interval of at
least 15 min. (B) Data from the three trials were pooled to highlight significant
differences between the experimental groups. Mice for each condition were as
follows: wt, Veh = 9; wt, LP-211 = 11; Het, Veh = 12; Het, LP-211 = 10. Data
are mean ± SEM. e : wt, Veh vs. Het, Veh, p < 0.05.
the LP-211 treatment did not affect the behavioral profile of
either wt or mutant mice in this test.
Barnes Maze Test
Acquisition
As expected, latency to locate (first nose poke) and to enter the
target hole decreased across trials during the acquisition phase
(main effect of days: F(4,148) = 22.78; p > 0.001; F(4,148) = 24.56;
p> 0.001, respectively), thus confirming that all the mice learned
to locate the target hole across the training sessions.
As a whole, mutant mice did not differ from wt controls
during the training trials (no genotype nor genotype by RM
interactions were found for any of the analyzed parameters).
Probe Tests
On the 21st day (24 h after the last training trial) and the
28th day of the treatment schedule (7 days after the first probe
test), the target hole was closed and the probe trials were
conducted to assess spatial reference memory retention. Data
were analyzed with the RM-ANOVA, with probe tests as within-
subject factor. During both probe tests,MeCP2-308 heterozygous
female showed a worse performance compared to wt controls,
as demonstrated by the longer latency to the first nose poke
in the virtual target hole (primary latency) (p < 0.05 after
post hoc comparisons on the genotype by treatment interaction:
F(1,37) = 7.89; p = 0.008; Figure 4A) and the higher number
of primary errors RTT mice performed (p < 0.05 after post
hoc comparisons on the genotype by treatment interaction:
F(1,37) = 4.41; p = 0.043; Figure 4B (Moretti et al., 2006).
Importantly, LP-211 was able to reverse this impairment and
restored wt-like levels of both parameters (p< 0.05; Figure 4).
An increase in both parameters, suggestive of a worse
performance in this cognitive test, was also evident in wt mice
FIGURE 4 | Stimulation of the 5-HT7 receptor by LP-211 improves
spatial memory of MeCP2-308 female mice in the Barnes Maze test.
MeCP2-308 female mice (Het, Veh) displayed longer primary latencies (A) and
a higher number of primary errors (B) to locate the virtual target hole (first nose
poke in the virtual target hole) during the Probe tests. LP-211 treatment
partially restored the levels of both parameters in Het mice (A,B). Mice for
each condition were as follows: wt, Veh = 9; wt, LP-211 = 11; Het, Veh = 12;
Het, LP-211 = 10. Data are means ± SEMs. e : wt, Veh vs. Het Veh, p < 0.05
and * : Het, Veh vs. Het, LP-211, p < 0.05.
treated with LP-211 compared to veh-treated controls (p< 0.05).
Interestingly, during both probe tests all the experimental groups
showed a comparable profile. Consistently, the RM-ANOVA did
not yield significant effects of repeated measurements (Probe
1 and Probe 2), or genotype by RM or treatment by RM
interactions.
Electrophysiology Experiments
LTP was induced in CA1 area by TBS delivered to the Schaffer
collaterals in hippocampal slices from wt andMeCP2-308 female
mice, treated with either LP-211 or vehicle. TBS resulted in
a long-lasting increase of fEPSP slope both in wt and in
MeCP2-308 female mice (Figure 5). The RM-ANOVA revealed
a significant main effect of RM (F(48,912) = 8.14; p > 0.001) and
a significant genotype by treatment interaction (F(1,19) = 6.74;
p = 0.018). Post hoc comparisons by Tukey’s test on the genotype
by treatment interaction showed a trend towards a reduction in
the synaptic potentiation after TBS in vehicle-treatedMeCP2-308
females with respect to vehicle-treated wt (Figure 5). A clear
effect of the in vivo treatment was observed in RTT mice:
LP-211 induced a significant increase in synaptic potentiation
with respect to vehicle-treated MeCP2-308 females (p < 0.05;
Figure 5), while the same treatment did not modify the degree
of LTP in wt mice.
Molecular Pathways Related to Protein Synthesis
To determine whether the molecular modifications we detected
at the end of a seven-day long treatment with LP-211 in the brain
of RTT mice persist (De Filippis et al., 2014a), the amount and
activation of rp-S6 were analyzed by western blot analyses in
the hippocampi collected after a washout period of 2 months
from the last (7th) ip injection of either LP-211 or vehicle. The
ANOVA did not yield either genotype or treatment effects as for
total rpS6 protein level (Figure 6). Phosphorylation levels of the
rpS6 was generally reduced in the hippocampus of MeCP2-308
female mice (Figure 6), thus confirming the profile reported in
MeCP2-mutated males (Ricciardi et al., 2011; De Filippis et al.,
2014a). Such effect was however more marked at Ser240/244,
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FIGURE 5 | Treatment with LP-211 improves long-term potentiation
(LTP) in MeCP2-308 female mice. Field EPSPs (fEPSPs) were recorded in
the CA1 area of hippocampal slices; LTP was induced by theta burst
stimulation (TBS) of Schaffer collaterals. (A) MeCP2-308 female mice (Het,
Veh) showed a reduced LTP compared to wt littermate controls (wt, Veh).
(B) The LP-211 treatment significantly increased the response to TBS in
MeCP2-308 mice (Het, LP-211) with respect to Het controls. (C)
Comparison of the time courses of fEPSP slope after TBS did not show
significant differences between LP-211-treated Het and wt mice, thus
confirming a rescue of LTP in Het mice treated with LP-211. (D) LP-211
treatment did not affect the response to TBS in wt mice (wt, LP-211). Data
are mean ± S.E.M. The number of slices for each condition was as follows:
wt, Veh = 6; wt, LP-211 = 7; Het, Veh = 5; Het, LP-211 = 5. The inset shows
representative fEPSPs recorded before TBS and 40 min after TBS. Each
trace is the average
(Continued)
FIGURE 5 | Continued
of three successive fEPSPs (artifacts of stimulation have been truncated).
Calibration bars: 0.5 mV, 10 ms.
than at Ser235/236 (main effect of genotype: p-rpS6 (235/236):
F(1,12) = 3.86; p = 0.073; p-rpS6 (240/244): F(1,12) = 238.03;
p< 0.001; Figure 6).
Consistently, the ratio between the phosphorylated forms
and the total rpS6 protein content, which provides an
index of the net functionality of the kinase, was shifted
toward decreased phosphorylation (inactivation) in RTT mouse
hippocampus compared to wt controls (main effect of genotype:
Total p-rpS6/rpS6: F(1,12) = 12.75; p < 0.001). Of note,
LP-211 treatment significantly increased the levels of S6
phosphorylation in both genotypes (main effect of treatment:
p-rpS6 (236/238)/rpS6: F(1,12) = 46.84; p < 0.001; p-rpS6
(240/244)/rpS6: F(1,12) = 32.45; p < 0.001) and the total p-
rpS6/ rpS6 ratio (main effect of treatment: Total p-rpS6/rpS6:
F(1,12) = 8.99; p = 0.011), thus restoring wt-like levels of S6
phosphorylation in RTT mouse brain (Figure 6).
Discussion
The present study extends our previous findings (De Filippis
et al., 2014a) and demonstrates that a seven-day-long stimulation
of the 5-HT7 receptor significantly improves RTT-related
impairments in spatial reference memory and synaptic plasticity,
observed in symptomatic female mice modeling RTT. In
addition, a delayed beneficial effect of the LP-211 treatment on
general health status was also discovered in MeCP2-308 Het
female mice. Notably, treatment evaluation on behavioral and
molecular parameters was carried out up to 2 months after the
last injection. The present study thus provides evidence of long-
lasting beneficial effects of a transient LP-211 exposure on RTT-
related impairments.
Consistent with previous studies in males (Moretti et al.,
2006; De Filippis et al., 2010), we found that MeCP2-308
female mice show synaptic plasticity deficits, cognitive and
motor coordination impairment as well as slight, but reliable
phenotypic alterations. The present results in females confirm
that neurobehavioral alterations are detectable under conditions
of heterozygosis in RTTmouse models (Katz et al., 2012; Samaco
et al., 2013). As the estrous cycle was not controlled in this
study, we cannot completely exclude the possibility that cycle
genotype differencesmay have exerted a role, although this seems
unlikely (see the review paper: Prendergast et al., 2014). Of
note, all the alterations we uncovered in RTT female mice were
counteracted by a seven-day long treatment with LP-211. These
include the phenotypic alterations, the impairments in cognitive
and synaptic plasticity, as well as motor coordination deficits.
Taken together with our previous study (De Filippis et al., 2012),
these results provide evidence that a LP-211 treatment exerts a
widespread beneficial effect on RTT-related symptomatology in
a mouse model. Moreover, our data demonstrate that the agonist
administration is equally effective when tested in the gender
and the hormonal milieus which are more relevant for RTT
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FIGURE 6 | Long-lasting beneficial effects of the stimulation of the
5-HT7 receptor on RTT-related alterations in rpS6 activity in mouse
hippocampus. (A) Representative Western blot analysis (summarized view
corresponding to one animal per group) of rpS6, p-rpS6 Ser 235/236, p-rpS6
Ser 240/244 and β-actin proteins in hippocampi of MeCP2-308 female mice
(Het) and wt mice in control conditions (Veh) or treated with LP-211. In order to
limit background and unspecific signals, the membranes related to rpS6 and
p-rpS6 Ser 240/244 were cut at the opportune kDa range with the help of the
MW marker before hybridization. (B) Semi-quantitative densitometric analysis,
obtained by optical density (OD) of rpS6 signals normalized with OD of β-actin
signals. OD ratios are expressed as the average fold increase vs. wt controls.
N = 4 per each experimental groups. Data are mean ± SEM. e: wt, Veh vs. Het,
Veh; p < 0.05; *: Veh vs. LP-211, p < 0.05; ee: wt, Veh vs. Het, Veh; p < 0.01;
**: Veh vs. LP-211, p < 0.01.
(Katz et al., 2012), certainly increasing the translational value of
the present study.
Our results provide further evidence that stimulation of
5-HT7 receptors acts consistently onto spatial memory and
synaptic plasticity (Roberts and Hedlund, 2012; Volpicelli et al.,
2014). As a whole, these data add to a complex picture in which
5-HT7 receptor agonists and antagonists have been reported
to have both promnesic and/or anti-amnesic effects (Meneses
et al., 2015), with major results pointing to an involvement
of the 5-HT7 receptor in spatial memory (Hedlund, 2009;
Sarkisyan and Hedlund, 2009; Beaudet et al., 2015). Interestingly,
we found that the effects of the LP-211 treatment strongly
depend on the basal level of performance, thus confirming
previous studies (Meneses et al., 2015). In the Barnes Maze
test, for instance, we found that the LP-211 treatment improved
the defective performance of RTT mutants, while dampening
the spatial memory of normal mice. This feature is certainly
of high relevance in a translational context, in which a
normalization of abnormal performances represents the most
attractive outcome.
Interestingly, the beneficial effects of the treatment over the
general health status of RTT mice became evident 3 weeks
after the last administration of LP-211, possibly as a result of
stimulated neuroplasticity. In other words, some weeks may
be needed before the consequences of 5-HT7R stimulation
appear, in the form of a general improvement of RTT-
related neurological alterations. In particular, the phenotypic
parameters which appeared to be improved in treated RTT
mice include the fur, the abnormal gait, the kyphosis and the
breathing abnormalities. Further studies are however needed
to verify whether such effect results from an improvement
in those autonomic functions which are related to aberrant
serotonergic signaling in RTT, such as the respiratory brainstem
dysfunction (Abdala et al., 2010, 2014). Plethysmograpic analyses
will certainly help shedding light on this possibility and to
corroborate our general health scoring.
By contrast, a seven-day-long treatment with LP-211
appeared to provoke a transient worsening of the general
condition of wt mice and of their performance in the Dowel test
and the Barnes Maze task. Phenotypic features which appeared
most compromised in LP-211-treated wt mice include mobility
and fur. Interestingly, we have previously reported that sub-
chronic treatment with LP-211 reduces the 5-HT7R expression
in wt mouse hippocampus, to levels comparable to those found
in RTT mouse brain (De Filippis et al., 2014a). Note however
that present wt mice were aged 1 year, and that a comparable
treatment during adolescent age resulted in a potentiation of
forebrain connectivity to the hippocampus, of 5-HT7R function
in the septum as well as of spatial memory skills (Altabella et al.,
2014; Canese et al., 2015). It will be interesting to determine
whether the direction of LP-211 effects may depend on age, and
whether modulated expression of the 5-HT7R in rodent brains
may account for the phenotypic effects of a subchronic LP-211
treatment.
One major conclusion of our study concerns the enduring
sequelae exerted by a seven-day-long treatment with LP-211 in
RTT mice. Even though further studies are needed to uncover
the neurobiological mechanisms underlying such effects, we
argue that they may have been mediated by LP-211-induced
activation of Rho GTPases, a family of proteins crucially involved
in intellectual disability disorders (Ramakers, 2002; De Filippis
et al., 2014b). Our previous data do in fact demonstrate that the
effects of a single intra-cerebro-ventricular injection with CNF1,
a bacterial protein known to transiently activate Rho GTPases,
were still well evident after months in a RTT mouse model
(De Filippis et al., 2012). In the same study, we unequivocally
demonstrated the crucial role played by Rho GTPases: the
abolition of the CNF1 activity over the activation status of Rho
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GTPases was sufficient to prevent the beneficial effects of this
focal CNF1 treatment.
Rho GTPases are a family of proteins which plays a crucial
role in the regulation of synaptic plasticity, synaptogenesis
and dendritic spine formation (Luo, 2000; Etienne-Manneville
and Hall, 2002; Hall, 2005). Hence, it may be speculated that
plastic remodeling of the neural circuitries might account, in
RTT mouse brains, for the apparent long-lasting effects of
pharmacological approaches targeting Rho GTPases, like CNF1
and LP-211 (Diana et al., 2007; Cerri et al., 2011; De Filippis
et al., 2012; Loizzo et al., 2013). In this line, we have recently
demonstrated that a sub-chronic treatment with LP-211 during
adolescence, a time window of increased plasticity of the central
nervous system (Adriani et al., 2006), induces a persistent
rearrangement of neural circuitries in rats (Altabella et al., 2014).
A similar neuroplastic effect might thus account for the long-
lasting beneficial effects of LP-211 we presently report in RTT
mice. Further studies are however needed to clarify this point.
Notably, we found that the molecular effects of LP-211
treatment over the activation status of the rpS6, the downstream
target of mTOR and S6 kinase responsible for the altered
protein translational control in RTT mouse brain (Ricciardi
et al., 2011), were still well evident after 2 months from the last
injection of LP-211 in RTT mouse hippocampus. Even though
the relative role of these molecular effects at the phenotypic
level is still unclear, such results are particularly interesting
as the normalization of this signaling pathway in an in vitro
RTT human model is known to rescue disease-related cellular
impairments (Li et al., 2013). We cannot at the moment
explain how this persistent molecular effect is achieved, and
further studies are needed. We can, however, certainly exclude
that it can be related to brain accumulation of LP-211 or to
persistent binding to the 5-HT7R, based on previous studies
demonstrating that LP-211 is no longer detectable inmouse brain
after 120 min from a single (10 mg/kg, ip) injection (Leopoldo
et al., 2008).
Conclusion
Overall, the present study extends previous findings from our
laboratory, also highlighting persistent effects, and provides
compelling preclinical evidence of the potential therapeutic value
of a pharmacological approach targeting the brain serotonin
receptor 7. This innovative approach may turn out to be relevant
for RTT, a devastating disorder for which no cure is currently
available. The high potential of innovative drugs, capable of
targeting the activation status of the Rho GTPases family, is also
further supported. Given the promising results so far obtained
at the preclinical level, any effort to narrow the gap between
preclinical and clinical research is now urgent and mandatory.
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